NLS Pharmaceutics AG (NLSP)
After hours:
| Previous Close | 1.0300 |
| Open | 1.0300 |
| Bid | 0.9301 x 1800 |
| Ask | 0.9524 x 1300 |
| Day's Range | 0.9301 - 1.0400 |
| 52 Week Range | 0.9300 - 7.3500 |
| Volume | |
| Avg. Volume | 3,841,177 |
| Market Cap | 13.864M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6910 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
NLS Pharmaceutics Invites Patients, Caregivers and Other Interested Parties to Attend International Narcolepsy Webinar
ZURICH, SWITZERLAND / ACCESSWIRE / January 12, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that Wake Up Narcolepsy, a leading patient advocacy organization dedicated to serving the narcolepsy community, will host an online International Narcolepsy Webinar taking place on Ja
- ACCESSWIRE
NLS Pharmaceutics Announces Patent Issuance in the United States for its Mazindol Extended-Release Formulation
* Key patent now granted in major markets including the U., Europe, Canada & South Korea * Patent claims cover use of the Company's lead product candidate, Quilience® (mazindol ER) in both attention deficit hyperactivity disorder (ADHD) & narcolepsySTANS, SWITZERLAND / ACCESSWIRE / January 4, 2022 / NLS Pharmaceutics Ltd.
- ACCESSWIRE
NLS Pharmaceutics Announces Preclinical Results Confirming the Potential Benefit and Safety Profile of NLS-4 for Circadian Rhythm Dysregulation and Chronic Fatigue Syndrome in Long-Covid Model
STANS, SWITZERLAND / ACCESSWIRE / November 30, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces final results from a preclinical study for NLS-4 (Lauflumide), the Company's next-generation wake-promoting drug candidate.
